IFNA1 and systemic lupus erythematosus: Humanized anti-IFNα monoclonal antibodies have been developed and have been tested in phase I trials in patients suffering from systemic lupus erythematosus (SLE) and psoriasis, autoimmune diseases in which IFNα is believed to play a critical role.